In the United States, the compound's unapproved status also intersects with compounding policy: the FDA has publicly categorized BPC-157 among substances it has flagged for pharmacy compounding review, reflecting the agency's position that available data are insufficient to support that use
Its most cited wound-healing paper, Malinda et al., J Invest Dermatol 1999, showed that T4 increased re-epithelialisation by roughly 42% at four days and up to 61% at seven days in a full-thickness rat wound model, with greater collagen deposition and angiogenesis
Hydroxocobalamin BNF Drug Monograph
Patient advocacy is importantif symptoms persist despite normal test results, request further investigation or specialist referral, as borderline B12 levels may still cause symptoms in some individuals
If you are uncertain, a healthcare provider can help distinguish between local reactions and true allergic responses